Clinicians’ Use of ‘Safer’ Opioid-Prescribing Practices Spotty
Tanezumab for OA Pain
Ibuprofen an Option for Early Pain Control after Hip Replacement
Canada Approves Erelzi for PsA; Plus FDA Moves to Increase Access to Naloxone
FDA Update: Priority Review for Non-Opioid Treatment & New Warning for Fluoroquinolones
The Perils of Pain Meds Revisited
FDA Approves Opioid Treatment
5-Year Data on Secukinumab in AS; Oliceridine Not Recommended for FDA Approval
Zilretta Promising for Blood Glucose Levels; Plus Filgotinib Promising for RA
- 1
- 2
- 3
- …
- 12
- Next Page »